Learning Objectives:

1.    Distinguish The  Pathophysiology  Between Diastolic (HFpEF) and Systolic (HFrEF) Heart Failure
2.    Discuss new Approaches to the Treatment of HFpEF: SGLT -2 Inhibition
3.    Review Randomized Trials (RCT)  In THE Treatment of HFpEF
      

 

Faculty Disclosure:

Javed Butler, MD, Presenter, works as a consultant with Abbot, Adrenomed, Amgen, Array, Astra Zeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CVRx, G3 pharmaceutical, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpoid, Medtroni, Merck, Novartis, Novo nordisk, Roche, and Vifor for heart failure. Dr. Butler is also on the speakers bureau with Novartis, Boehringer Ingelheim-Lilly, Astra Zeneca, Janssen on heart failure.

Faculty does not plan on discussing unlabeled/investigational uses of a commercial product.

Session date: 
01/05/2022 - 12:00pm to 1:00pm EST
Location: 
Boston University Medical Center
Boston, MA
United States
See map: Google Maps
Add to calendar: 
  • 1.00 AMA PRA Category 1 Credit™

    Boston University Chobanian & Avedisian School of Medicine designates this Live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.00 Participation
Please login or register to take this course.